RxDoctor Payments Data

Horacio Daubon-Del Valle, MD

Neurology · Bayamon, PRNPI 1467573204

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (57.6%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 10 manufacturers reported payments, led by Lilly USA, LLC at 59.4% of the total. Reporting peaked in 2019 at $15,305 and has fallen 99.0% since, to $150 in 2025. Among neurology clinicians in PR with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$20,980in general payments, 2019–2025

Across 79 payments — averaging $265.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$12K
  • Eli Lilly Export S.A. Puerto Rico Branch$8K
  • Eli Lilly$391
  • AbbVie$142
  • Immedica Pharma US, Inc.$127
  • Johnson & Johnson$93
  • plus $166 from 4 others

What the payments were for

  • Consulting fees$6,47531%
  • Speaking & faculty fees$12,07558%
  • Travel & lodging$1,0615%
  • Food & beverage$1,1756%
  • Education$1951%

General payments by program year

19
20
21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$20,980 in reported general payments places this provider in the 90th percentile of 129 neurology providers in Puerto Rico.

See all neurology providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$38,284
Medicare patients
94
Services billed
232

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Emgality PenGalcanezumab-Gnlm145$106,114
VimpatLacosamide31$36,011
BriviactBrivaracetam28$35,247
Nurtec OdtRimegepant Sulfate15$28,844
LamictalLamotrigine28$26,713
Memantine Hcl1,366$25,348
Keppra XrLevetiracetam12$18,626
AptiomEslicarbazepine Acetate14$17,853
Aimovig AutoinjectorErenumab-Aooe22$16,763
Lacosamide255$16,544
Levetiracetam525$15,948
Donepezil Hcl1,630$13,233
Rivastigmine85$10,198
KeppraLevetiracetam12$7,228
Oxcarbazepine61$5,021

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
UCB, Inc.Vimpat, Briviact$46$71,25759 claims
Sunovion Pharmaceuticals Inc.Aptiom$31$17,85314 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 129 neurology providers in Puerto Rico.

Other neurology in Bayamon

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →